[Molecular targeted therapy in lymphoid leukemias]

Kensuke Kojima, Toshihiko Ando, Shinya Kimura

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Recent advances in the treatment of lymphoid leukemias have incorporated molecular targeted drugs (CD20-targeting rituximab and BCR-ABL tyrosine kinase inhibitors) into the traditional chemotherapeutic agents. This article reviews novel molecular targeted therapies for patients with lymphoid leukemias including acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairly cell leukemia and HTLV-I-related adult T-cell leukemia. Investigational agents that will be discussed in this review include inotuzumab, blinatumomab, alemtuzumab, ofatumumab, ibrutinib, idelalisib, bafetinib, lenalidomide, ABT-199 and mogamulizumab. Novel approaches warrant continued research to improve outcomes for patients with lymphoid leukemias.

Original languageEnglish (US)
Pages (from-to)1094-1098
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Volume72
Issue number6
StatePublished - Jun 1 2014

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of '[Molecular targeted therapy in lymphoid leukemias]'. Together they form a unique fingerprint.

Cite this